FundingWatcher
Home / Startups / Top biotech startups / Biotech startups that raised Series C / Biotech startups that raised Series C in DACH

Biotech startups that raised Series C in DACH

Updated 16 Nov 2026

Reset
Biotech startups that raised Series C in DACH
One-time CSV
  • 35 funded companies, 21 with a website
  • Last round, amount, date, total raised and investors
  • CRM-ready CSV, 18 columns
  • Download right after payment
With founder contacts
Compiled to order
  • The full startup CSV, plus founders and executives
  • Up to 2 founders or CEOs per company, compiled to order
  • Name, job title and LinkedIn URL where found
  • Verified direct email per person
  • Startup CSV at once, contacts CSV by mail within 24 hours
Download right after paymentFree 10-row sampleSecure checkout by Stripe

Not sure about the data?

Download a free 10-row sample first. No account, no payment.

startups-biotech--series-c~dach.csv35 rows × 18 columns
CompanyCityLast roundAmountDate
4TEEN4 PharmaceuticalsHennigsdorfSeries C$36.1M2025-11-13
TubulisMunichSeries C$400.6M2025-10-15
CutissZürichSeries C$38.8M2025-09-10
NumabWädenswilSeries C$54.8M2025-01-09
ImmunOs TherapeuticsSchlierenSeries C$11.0M2024-09-17
Sphingotec GmbHHohen NeuendorfSeries C$5.5M2024-08-08
AsceneuronLausanneSeries C$100.0M2024-07-16
Bright Peak TherapeuticsAllschwilSeries C$90.0M2024-06-11

8 rows of the CSV in 5 of its 18 columns.

35
Startups
$2.0B
Total raised
0
Funded in the last 12 months
0
Raised in the last 12 months

Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.

Newest rounds

15 of 35
15 rows
Company What they do Sector Location Last round Amount Date Total raised Investors Employees Founded
4TEEN4 Pharmaceuticals 4TEEN4 Pharmaceuticals develops therapies and biomarkers for diagnosing, predicting, and treating circulatory shock. Biotech Hennigsdorf, Germany Series C $36.1M 2025-11-13 $95.9M Wellington Partners, Brandenburg Kapital, HBM Healthcare Investments +1 11 to 50 2013
Tubulis Tubulis generates antibody-drug conjugates with unique properties for solid tumor indications. Biotech Munich, Germany Series C $400.6M 2025-10-15 $616.9M HTGF (High-Tech Gruenderfonds), Bayern Kapital, Seventure Partners +1 51 to 100 2012
Cutiss Cutiss is a life science company that produces regenerative medicine and engineers skin tissue. Biotech Zürich, Switzerland Series C $38.8M 2025-09-10 $94.6M Innosuisse 11 to 50 2017
ImmunOs Therapeutics ImmunOs Therapeutics is a clinical-stage biotechnology company. Biotech Schlieren, Switzerland Series C $11.0M 2024-09-17 Lightspeed Venture Partners, Innosuisse, Mission BioCapital +1 11 to 50 2014
Asceneuron Asceneuron develops therapeutics for orphan tauopathies and Alzheimer's disease. Biotech Lausanne, Switzerland Series C $100.0M 2024-07-16 OrbiMed, Novo Holdings, EQT Life Sciences +1 1 to 10 2012
Memo Therapeutics Memo Therapeutics conducts biotechnology research in antibody discovery and immune repertoire analysis. Biotech Schlieren, Switzerland Series C $22.0M 2024-05-07 $108.8M Verve Ventures, Kurma Partners, Pureos Bioventures +1 11 to 50 2012
NBE-Therapeutics NBE-Therapeutics develops oncology treatments for cancer patients. Biotech Basel, Switzerland Series C $22.0M 2020-01-10 $65.7M Novo Holdings, Boehringer Ingelheim Venture Fund, PPF Group 11 to 50 2012
dacadoo dacadoo offers digital lifestyle solutions through mobile apps from its base in Switzerland. Biotech Zürich, Switzerland Series C $71.1M 2019-12-13 Samsung Ventures 51 to 100 2010
Andrew Alliance Andrew Alliance is a Swiss pioneer in robotics for the life sciences sector. Artificial intelligence Geneva, Switzerland Series C $14.0M 2018-06-12 Venture Kick, Omega Funds, Rancilio Cube Sicaf 11 to 50 2011
Endosense Endosense develops medical technology that improves the reproducibility of catheter ablation for cardiac arrhythmias. Biotech Geneva, Switzerland Series C $41.2M 2013-11-27 3i Group, VI Partners, Andera Partners +2 51 to 100 2003
Viroblock Viroblock is a Swiss company developing antiviral technology for air filtration products. Biotech Geneva, Switzerland Series C $4.5M 2012-02-14 $4.5M StartAngels Network, BlueOcean Ventures 1 to 10 2005
GILUPI GILUPI develops medical devices that isolate rare cells from circulating blood in vivo. Biotech Potsdam, Germany Series C $4.8M 2011-01-13 $4.8M HTGF (High-Tech Gruenderfonds), KfW, Brandenburg Kapital +1 11 to 50 2005
MTM Laboratories MTM Laboratories manufactures in-vitro diagnostic tests for detecting and diagnosing cervical and other cancers early. Biotech Heidelberg, Germany Series C $9.7M 2010-11-08 $109.7M Wellington Partners, LBBW VC, Gilde Healthcare +2 1,001 to 5,000 1999
Synosia Therapeutics Synosia Therapeutics develops and commercializes products for unmet needs in psychiatry and neurology. Biotech Basel, Switzerland Series C $30.0M 2010-10-12 $94.0M Novo Holdings, Versant Ventures, 5AM Ventures +2 1 to 10 2006
Signature Diagnostics GmbH Signature Diagnostics GmbH develops translational oncology and genomics tests for cancer care. Biotech Potsdam, Germany Series C $7.6M 2008-08-12 KfW, BFB Fruehphasenfonds, EVP Capital Management +1 1 to 10 2004

Table 1. Biotech startups that raised Series C in DACH: the 15 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 35.

Most active investors

By companies backed
#InvestorTypeLocation CompaniesShare Funded, 12 monthsLatest
1 KfW Government investment office Frankfurt, Germany 7 20%
2 HTGF (High-Tech Gruenderfonds) Venture capital firm Bonn, Germany 5 14%
3 Brandenburg Kapital Government investment office Potsdam, Germany 3 9%
4 Wellington Partners Venture capital firm Munich, Germany 3 9%
5 HBM Healthcare Investments Venture capital firm Zug, Switzerland 3 9%
6 Novo Holdings Corporate venture arm Hellerup, Denmark 3 9%
7 Seventure Partners Venture capital firm Paris, France 2 6%
8 Andera Partners Private equity firm Paris, France 2 6%
9 Innosuisse Government investment office Berne, Switzerland 2 6%
10 BlackRock Investment bank New York, United States 2 6%
11 Venture Kick Startup incubator Schlieren, Switzerland 2 6%
12 StartAngels Network Angel group Zürich, Switzerland 2 6%
13 BioMedPartners Venture capital firm Basel, Switzerland 2 6%
14 BlueOcean Ventures Venture capital firm Plan-les-ouates, Switzerland 2 6%
15 3i Group Private equity firm London, United Kingdom 2 6%

Table 2. Biotech startups that raised Series C in DACH: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Sectors

SectorsCompaniesShareTotal raised
Health care 28 80% $2.0B
Software 6 17% $9.0M
Hardware 3 9%
Artificial intelligence 2 6%
Fintech 1 3%

Table 3. Biotech startups that raised Series C in DACH by sector. Source: FundingWatcher. Data as of 16 November 2026.

Funding stage

Funding stageCompaniesShareMedian last round
Series C 35 100% $13.5M

Table 4. Biotech startups that raised Series C in DACH by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.

Countries

CountriesCompaniesShare
Switzerland 20 57%
Germany 15 43%

Table 5. Biotech startups that raised Series C in DACH by headquarters country. Source: FundingWatcher. Data as of 16 November 2026.

Cities

CitiesCompaniesShare
Geneva 4 11%
Schlieren 3 9%
Munich 2 6%
Zürich 2 6%
Wädenswil 2 6%
Basel 2 6%
Berlin 2 6%
Potsdam 2 6%
Hennigsdorf 1 3%
Hohen Neuendorf 1 3%
Lausanne 1 3%
Allschwil 1 3%

Table 6. Biotech startups that raised Series C in DACH by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.

Most recent round by year

Most recent round by yearCompaniesShareRaised
2025 4 11% $530.3M
2024 5 14% $228.5M
2023 1 3% $25.9M
2022 1 3% $2.2M
2020 1 3% $22.0M
2019 4 11% $92.6M

Table 7. Biotech startups that raised Series C in DACH by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.

Founding year

Founding yearCompaniesShare
2015 to 2019 2 6%
2010 to 2014 15 43%
Before 2010 18 51%

Table 8. Biotech startups that raised Series C in DACH by founding year. Source: FundingWatcher. Data as of 16 November 2026.

Team size

Team sizeCompaniesShare
1 to 10 9 26%
11 to 50 18 51%
51 to 100 5 14%
101 to 250 1 3%
251 to 500 1 3%
1,001 to 5,000 1 3%

Table 9. Biotech startups that raised Series C in DACH by headcount. Source: FundingWatcher. Data as of 16 November 2026.

Method

Sources, fields and exclusions of both files: Method.

Questions

How many biotech startups in DACH whose last round is Series C are on the list?
35, in the file dated 16 November 2026.
What does the CSV contain?
One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
How much does the list cost?
$29 one-time for all 35 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
What arrives after payment?
At once: the CSV download link, on the page after payment and by mail.
Can I see rows before buying?
The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
How current is the data?
The file is dated 16 November 2026. The download link serves the current file each time it is opened.

Biotech startups that raised Series C in DACH: 35 rows, CSV, $29 one-time.

At once: the CSV download link, on the page after payment and by mail.

Columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.

With founder contacts: $199 one-time. List CSV right after payment; up to 2 verified founder or CEO emails per company compiled to order within 24 hours.

Not sure about the data?

Download a free 10-row sample first. No account, no payment.

Biotech at other stages in DACH

Other sectors that raised Series C in DACH

Cite: FundingWatcher, 35 biotech companies in DACH whose most recent round is Series C, 16 November 2026. https://fundingwatcher.com/startups/biotech/series-c/dach/